Hope Medicine announced global license agreement with Bayer AG to advance the development and commercialization of the monoclonal antibody directed against prolactin (PRL) receptor

        Hope Medicine Inc. Announced Dr. Henri Nico Doods as President and Head of Research & Clinical Development

        Hope Medicine completed US$56 million in Series B financing, strengthening capabilities of global innovation

        Hope Medicine Inc. Announced Dr. Henri Nico Doods as Chief Executive Officer

        Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in AGA Alopecia

        写意人物丨肖瑞平：打通转化医学的最后一公里

        创业老兵娄实的新起点 | 遇见

        创新工场陶宁：女性是科创时代不可或缺的力量 | 创观点

        启明创投主管合伙人梁颕宇：回报率不是判定项目的唯一标准

        致敬女创业者，我们采访了三位医疗玫瑰 | 创观点